التفاصيل البيبلوغرافية
| العنوان: |
Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan |
| المؤلفون: |
Vizza, Carmine Dario, Letizia, Claudio, Badagliacca, Roberto, Poscia, Roberto, Beatrice, Pezzuto, Cristina, Gambardella, Nona, Alfred, Silvia, Papa, Serena, Marcon, Mancone, Massimo, Iacoboni, Carlo, Riccieri, Valeria, Maurzio, Volterrani, Fedele, Francesco, Pezzuto, Beatrice |
| المصدر: |
International Journal of Cardiology. 167:220-224 |
| بيانات النشر: |
Elsevier BV, 2013. |
| سنة النشر: |
2013 |
| مصطلحات موضوعية: |
Adult, Male, medicine.medical_specialty, Hypertension, Pulmonary, Idiopathic Pulmonary Hypertension, Urology, pulmonary arterial hypertension, medicine.artery, medicine, Humans, Familial Primary Pulmonary Hypertension, Prospective Studies, Antihypertensive Agents, Aged, Sulfonamides, bosentan, clinical worsening, business.industry, Middle Aged, Brain natriuretic peptide, medicine.disease, Pulmonary hypertension, Endothelin 1, Bosentan, Surgery, Adrenomedullin, Treatment Outcome, endothelin-1, medicine.anatomical_structure, Pulmonary artery, Exercise Test, Vascular resistance, Female, Cardiology and Cardiovascular Medicine, business, Biomarkers, Follow-Up Studies, medicine.drug |
| الوصف: |
article i nfo Objectives: To address if baseline endothelin-1 (ET-1) plasma levels might predict clinical worsening (CW) in patients with idiopathic pulmonary hypertension (IPAH) treated with bosentan. Methods: Forty-four consecutive patients with IPAH (WHO classes II-III) were included in this study. After an initial assessment (clinical status, pulmonary hemodynamics, samples for adrenomedullin (ADM), ET-1 and brain natriuretic peptide (BNP) plasma levels), patients were treated with bosentan and followed-up for CW. Results: We observed CW in 24 patients. Actuarial rates of freedom from CW were 74% at 1 year, 56% at 2 years, and 43% at 3 years. Patients with CW had a worse WHO functional class (II/III; no-CW 14/6 vs CW 5/19, p=0.002), six- minute walk-test distance (no-CW 439+94 m vsCW 385+82 m, p=0.04), mean pulmonary artery pressure (no- CW 47.4+10.6 mm Hg vs CW 56+12.6 mm Hg, p=0.02) and pulmonary vascular resistance (PVR no-CW 12.5+ 4.8 WU vs CW 16.4+6.3 WU, p=0.03) than the no-CW group. Moreover ET-1 (no-CW 14.1+4.2 pg/ml vs CW 21.3+6.3 pg/ml, p=0.0001), ADM (no-CW 14.9+7 pg/ml vs CW 21.5+10.4 pg/ml p=0.002) and BNP (no- CW 82.8+35.3 pg/ml vs CW 115.4+39.6 pg/ml, p=0.007) plasma levels were significantly higher in the CW group than in the no-CW group. The multivariate Cox proportional hazards model identified WHO class III (RR 4.6, 95%CI 14.6-1.45), ET-1 plasma levels (RR 1.1, 95%CI 2.05-1.01) and PVR (RR 1.2, 95%CI 1.3- 1.03) as indepen- dent risk factors for CW. Conclusions: These data confirm the high rate of CW in patients with IPAH treated with bosentan and document the impact of the endothelin system on CW of these patients. © 2011 Published by Elsevier Ireland Ltd. |
| تدمد: |
0167-5273 |
| الوصول الحر: |
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c0b46e52544ac0bcd5ac3dfcf02bd3Test
https://doi.org/10.1016/j.ijcard.2011.12.104Test |
| حقوق: |
OPEN |
| رقم الانضمام: |
edsair.doi.dedup.....33c0b46e52544ac0bcd5ac3dfcf02bd3 |
| قاعدة البيانات: |
OpenAIRE |
